QC
NVAX icon

QCM Cayman’s Novavax NVAX Stock Holding History

QCM Cayman’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,600
Closed -$290K – 227
2020
Q4 		$290K Hold
2,600
– – 0.3% 115
2020
Q3 		$282K Sell
2,600
-247
-9% -$30.1K 0.49% 79
2020
Q2 		$237K Buy
+2,847
New +$109K 0.54% 78
2018
Q1 		– Sell
-1,291
Closed -$32K – 167
2017
Q4 		$32K Buy
+1,291
New +$31.5K 0.13% 113
2017
Q2 		– Sell
-939
Closed -$24K – 338
2017
Q1 		$24K Buy
+939
New +$25.8K ﹤0.01% 399
2016
Q1 		– Sell
-667
Closed -$112K – 234
2015
Q4 		$112K Buy
+667
New +$103K 0.09% 111

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

QCM Cayman's NVAX Position: Q1 2021 in Review

QCM Cayman sold out of Novavax (NVAX) in Q1 2021, closing a stake of 2,600 shares — an estimated $290K sold.

QCM Cayman first reported a position in NVAX in Q4 2015 and held it in 6 quarters. The position peaked at $290K in Q4 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

  • QCM Cayman reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
  • QCM Cayman sold 2,600 Novavax shares in Q1 2021, an estimated $290K.
  • QCM Cayman first reported a position in Novavax in Q4 2015 and held it in 6 quarters.
  • QCM Cayman's Novavax position peaked at $290K in Q4 2020.
  • 389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on QCM Cayman's 13F filing for Q1 2021, filed 17 May 2021.